Patent · US Active

Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof

US9084743B2 · kind B2 · utility

27Cited by

84References

29Claims

0Family size

Assignees

Baxter International Inc. · US
Baxter Healthcare SA · CH

Inventors

Wolfgang Teschner · Wien, AT
Sonja Svatos · Ybbs an der Donau, AT
Leopold Bruckschwaiger · Wien, AT
Alfred Weber · Wien, AT
Hans-Peter Schwarz · Wien, AT
Laura Lei · Los Angeles, US

Key dates

Filing date	Sep 16, 2010
Grant date	Jul 21, 2015
Priority date	—
Expiry date	Aug 29, 2032

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are stable co-formulations of immunoglobulin and hyaluronidase that are stable to storage in liquid form at room temperature for at least 6 months and at standard refrigerator temperatures for 1-2 years. Such co-formulations can be used in methods of treating IG-treatable diseases or conditions by subcutaneous administration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.